AlphAIalphai — Financial news for AI agents
investing.comSEP 11 min read$TEM

Tempus AI stock rises on Piper Sandler upgrade to Overweight

Tempus AI Inc (TEM) shares rose 2.1% premarket after Piper Sandler upgraded it to Overweight with a $76 price target. Analyst David Westenberg cited three growth drivers, including the pending Personalis acquisition and FDA approval of tumor-only xT CDx. The previous Neutral rating was due to AI sentiment driving valuation.

Original reporting
investing.com
Published Sep 1, 2026, 12:48 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 1:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefMarket movers
Primary signal
$TEM
Bullish
high confidence
Mentioned
$TEM
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$TEMBullishMed
01

Why it matters

The upgrade highlights new growth levers, potentially re‑rating the stock.

02

Market read

Analyst upgrade with a higher price target is a fresh catalyst that can move the stock in the near term.

03

What to watch

Execution risk of the Personalis acquisition and regulatory timelines for xT CDx.

Relevance 7/10Novelty 7/10Timing: premarket today

Background

Tempus AI is a diagnostics and data company focusing on AI‑driven tumor sequencing.

Company-level read

Ticker impact

$TEMBullishHigh confidence
Context

Piper Sandler upgraded Tempus AI to Overweight and raised price target to $76, driving a 2.1% pre‑market rise.

Expected impact

Potential further upside toward the $76 target in the short term.

Evidence & confidence

Upgrade includes concrete growth drivers and a 35% target increase, indicating material catalyst.

Market effects

Sector

Positive sentiment may lift other AI‑driven diagnostics firms.

Regional

U.S. biotech/health‑tech sector could see modest gains.

Global

Limited to investors tracking AI‑enabled healthcare stocks.

Counterpoint

What could challenge this read

Upgrade may be premature if integration of Personalis faces delays.

Key entities

  • Analyst
    Piper Sandler

    Equity research firm that issued the upgrade.

  • Target Company
    Personalis

    Acquisition target providing a tumor‑informed MRD platform.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 1
High

Why is Tempus AI stock rallying today?

Tempus AI stock rose 2.7% in pre-market trading after Piper Sandler upgraded it to Overweight with a $76 price target, citing growth catalysts. Canaccord Genuity reiterated its Buy rating and $80 target, praising the company's Personalis acquisition. Tempus AI reported Q2 profitability and raised 2026 revenue guidance to $1.6B. The move contrasts with broader market declines.

investing.com2 min
AUG 27
$TEMMedAI 9/10

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Tempus AI (TEM) shares rose after Moderna and Merck reported positive Phase 3 trial results for a personalized cancer therapy, validating Personalis' sequencing technology. Tempus agreed to acquire Personalis for $1.5B, with the deal pending. Personalis' technology is distinct from the main target of the acquisition, NeXT Personal, a tumor-informed molecular residual disease test. Tempus reported 9,000 MRD tests in Q2, while Personalis generated $22.357M in revenue and delivered 10,384 clinical

insidermonkey.com3 min